81 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Sell
Article Searches
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks? https://www.fool.com/investing/2019/01/24/does-johnson-johnsons-grim-outlook-spell-trouble-f.aspx?source=iedfolrf0000001 Jan 24, 2019 - Here's why comments from J&J executives about the future of pharmaceuticals made investors so nervous.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-ZC-FT-349786 Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
A Cure for Cancer Next Year? The Stock Market Says Don't Believe the Hype https://www.fool.com/investing/2019/01/30/a-cure-for-cancer-next-year-the-stock-market-says.aspx?source=iedfolrf0000001 Jan 30, 2019 - Israeli scientists claim they have a cure for cancer. Investors' response? The proof is in the pudding.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate http://www.zacks.com/stock/news/350873/roche-halts-two-late-stage-studies-on-alzheimers-candidate?cid=CS-ZC-FT-350873 Jan 30, 2019 - Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
What's in the Cards for Skyworks (SWKS) in Q1 Earnings? http://www.zacks.com/stock/news/351009/whats-in-the-cards-for-skyworks-swks-in-q1-earnings?cid=CS-ZC-FT-351009 Jan 31, 2019 - Skyworks (SWKS) is benefiting from its portfolio strength, particularly in the 5G applications and IoT market.
Merck (MRK) Tops on Q4 Earnings & Sales, Stock Up http://www.zacks.com/stock/news/351474/merck-mrk-tops-on-q4-earnings-sales-stock-up?cid=CS-ZC-FT-351474 Feb 01, 2019 - Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Stock is up in pre-market trading.
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/351811/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-351811 Feb 04, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Flip the Script: Drugmakers Blame Middlemen for Price Increases https://www.wsj.com/articles/flip-the-script-drugmakers-blame-middlemen-for-price-hikes-11549364401?mod=pls_whats_news_us_business_f Feb 05, 2019 - Under pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They’re not raising prices to make money or to cover research costs, but rather to pay a cut to middlemen in the supply chain.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.

Pages: 123456...9

Page 1>